Novo Nordisk R&D Organization and Pipeline Update

Novo Nordisk A/S is holding a special call to discuss its R&D and pipeline progress. Martin Lange, EVP of R&D and CSO, will present the company's new R&D organization, which was created 5 years ago. The call will focus on the pipeline and R&D events, including those presented at the 61st Edition of EASD in Vienna. Participants will have the opportunity to ask questions and discuss the pipeline and R&D progress with Martin.

Novo Nordisk A/S is set to hold a special call on September 12, 2025, to discuss its recent research and development (R&D) and pipeline progress. Martin Lange, Executive Vice President of R&D and Chief Scientific Officer, will present the company's new R&D organization, which was established five years ago. The call will delve into the pipeline and R&D events, including those presented at the 61st Edition of the European Association for the Study of Diabetes (EASD) in Vienna. Participants will have the opportunity to ask questions and discuss the pipeline and R&D progress with Lange.

The special call comes at a critical time for Novo Nordisk, as it continues to expand its access to GLP-1 therapies across diabetes and obesity. The company recently announced that the European Medicines Agency approved an updated Rybelsus label to reflect cardiovascular benefits in type 2 diabetes, following the results of the SOUL trial presented at the EASD 2025 Congress in Vienna. This approval positions Rybelsus as the first oral GLP-1 therapy in the EU with proven cardiovascular benefit, potentially expanding its clinical reach among patients with type 2 diabetes at increased cardiovascular risk Novo Nordisk (CPSE:NOVO B) Is Up 5.2% After Rybelsus Wins EU Cardiovascular Label Update – Has The Bull Case Changed?^[2].

Novo Nordisk's long-term investment narrative remains focused on expanding access to GLP-1 therapies, supported by product innovation and regulatory wins. The recent Rybelsus cardiovascular label approval in the EU is a significant step forward for clinical positioning, but it does not materially shift the short-term focus, which remains on the US regulatory process for similar label extensions and addressing near-term risks of price erosion and ongoing issues with compounded GLP-1 products in major markets Novo Nordisk (CPSE:NOVO B) Is Up 5.2% After Rybelsus Wins EU Cardiovascular Label Update – Has The Bull Case Changed?^[2].

Investors should also be aware of emerging threats, such as the accelerating risk from generic semaglutide launches in international markets. Despite these challenges, Novo Nordisk's outlook projects DKK396.7 billion in revenue and DKK142.5 billion in earnings by 2028, based on an annual revenue growth rate of 8.3% and a rise in earnings of DKK31.4 billion from the current DKK111.1 billion Novo Nordisk (CPSE:NOVO B) Is Up 5.2% After Rybelsus Wins EU Cardiovascular Label Update – Has The Bull Case Changed?^[2].

The special call will provide valuable insights into Novo Nordisk's R&D strategy and pipeline, allowing investors to better understand the company's long-term prospects. As the market continues to evolve, with new competitors and regulatory challenges, Novo Nordisk's ability to innovate and adapt will be key to maintaining its market leadership in diabetes and obesity treatments.

References
Eli Lilly stock rises as oral diabetes drug outperforms Novo Nordisk rival^[1] https://www.investing.com/news/stock-market-news/eli-lilly-stock-rises-as-oral-diabetes-drug-outperforms-novo-nordisk-rival-93CH-4242526
Novo Nordisk (CPSE:NOVO B) Is Up 5.2% After Rybelsus Wins EU Cardiovascular Label Update – Has The Bull Case Changed?^[2] https://simplywall.st/stocks/dk/pharmaceuticals-biotech/cph-novo-b/novo-nordisk-shares/news/novo-nordisk-cpsenovo-b-is-up-52-after-rybelsus-wins-eu-card